Objective
to demonstrate that the COBRA PzF stent with 14 days of DAPT post-stenting was superior in terms of bleeding and noninferior in terms of thromboembolic events when compared to new-generation DES and 3 to 6 months of DAPT post-stenting
Study
prospective, multicentre, open-label, parallel group-randomised trial(noninferiority margin 5%)
Population
patients with stable or unstable angina or acute coronary syndrome and oral anticoagulation
Endpoints
bleeding: BARC Class 2 (occurring beyond 14 days and 6 months), thromboembolic within 14 days
Conclusion
among patients with an indication for oral anticoagulation undergoing PCI, COBRA PzF was not superior with respect to bleeding events and not noninferior with respect to thromboembolic events
Byrne et al. Circulation Cardiovasc Interv. 2024 Oct;17:e013735